3rd Obesity and Weight Loss Drug Development Summit West

Optimizing Tolerability, Quality of Weight Loss and Personalized Therapies to Drive Competitive Drug Development

As obesity drug development enters a defining new chapter, the race is no longer about developing the next GLP-1, but delivering the next breakthrough in tolerability, muscle preservation, patient adherence, precision medicine, and long-term outcomes. With hundreds of obesity assets in development and billions of dollars invested in the space, 2026 is a pivotal moment for companies to differentiate their pipelines, benchmark their strategies, and secure their position in the market.

The 3rd Obesity and Weight Loss Drug Development Summit West is where the industry's most innovative pharma and biotech leaders come together to answer the questions that will shape the next decade of obesity therapeutics. While many events focus on clinical readouts or broad discussions around obesity care, this summit is dedicated to the practical challenges and strategic decisions driving drug development success.

Bringing together 80+ senior executives, and decision-makers, this intimate, industry-focused forum offers unparalleled opportunities to exchange insights, build meaningful partnerships, and understand what today's innovation really means for tomorrow's therapies. If you're serious about advancing next-generation obesity therapeutics, this is the room you need to be in.

URLs:
Website: https://go.evvnt.com/3822677-0?pid=2874
Brochure: https://go.evvnt.com/3822677-3?pid=2874

Category: Conferences | Science, Health and Medicine | Pharmaceuticals

Prices:
Vendor and Solution Provider - Conference Only: USD 3499.00,
Drug Developer and Research Institute: USD 0.50

Speakers: Adam Mendelsohn, Chief Executive Officer, Vivani, Ashok Bhandari, Executive Vice President and Chief Discovery Officer, Protagonist Therapeutics, Ben Pope, Founder and Chief Executive Officer, Mellicell, Charles Harris, Associate Vice President, Eli Lilly and Co., Frank Czerwiec, Chief Medical Officer, Sparrow Pharma, Gordon Foulkes, Founder and Chief Executive Officer, Lipidio Pharmaceuticals, Hans Keirstead, Chairman, Immunis, Jeremiah Bearss, Vice President - Clinical Development, Biolexis Therapeutics, Joanne Hsieh, Head of Metabolism, Gordian Biotechnology, John Dobak, CO-Founder and Chief Executive Officer, Clic Bio, John Liles, Vice President - Biology and Translational Science, Moonwalk Biosciences, Maria Wilson, Executive Director, CVRM, Genentech, Mark Esposito, Founder and Chief Scientific Officer, KayoThera, Meltem Zeytinoglu, Executive Medical Director, Eli Lilly and Co., Mini Balakrishnan, Vice President, Biology, Biomea Fusion, Nathaniel Wang, Co-Founder and CEO, Replicate Bioscience, Patrick Griffin, Founder and CEO, Incregen Therapeutics, Stanley Watowich, Founder and Chief Executive Officer, Ridgeline Therapeutics